SPÓŁKA AKCYJNA
Biomaxima
Biomaxima Spółka Akcyjna
KRS: 0000313349NIP: 9462360625REGON: 432519331Share capital: 4.2 M PLN
Chemical manufacturing20.59.ZManufacture of other chemical products n.e.c.
VETTERÓW, 5, 20-277, LUBLIN, POLSKAActive
SPÓŁKA AKCYJNA
Biomaxima
Biomaxima Spółka Akcyjna
SPÓŁKA AKCYJNA
Listed on the Warsaw Stock ExchangeBiomaxima Spółka Akcyjna
Biomaxima Spółka Akcyjna (KRS 0000313349, NIP 9462360625) is a Polish company, headquartered in Lublin, Lubelskie voivodeship. Biomaxima operates in: Manufacture of other chemical products n.e.c. (PKD 20.59.Z). Industry: Chemical manufacturing. The company has been listed in the National Court Register since September 10, 2008. Biomaxima's most recently reported net revenue was 56.1 M PLN for 2024.
Market capitalisation
39.46M PLN
Ranked #231 among the largest Polish companies in WIG-POLAND.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Other activities
Credibility rating
61.9 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/18 yrs
Board changes
9
9/18 yrs
PKD changes
2
2/18 yrs
Name changes
0
0/18 yrs
Data from 18 years of registry activity.
Payment reliability score from 2012–2024
Current: C (62/100)
Trend: deteriorating (-11.2 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Standard limit from 2012–2024
Current: 1.6 M PLN
Safe: 699.4 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Listed on the Warsaw Stock Exchange
BMXISIN: PLBIOMX00015Główny Rynek
Ranked #231 in WIG-Poland
Founded
September 10, 2008
17 years in operation
Legal form
SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
LUBLIN
LUBELSKIE
Primary PKD
20.59.Z
Manufacture of other chemical products n.e.c.
Share capital
4.2 M PLN
Board
3 people
Sup. board: 5 · Proxies: 1
Filed years
11 years
2012–2024 · profitable: 9/11
Registry entries
118
latest: June 17, 2026
Revenue
56.1 M PLN
2024
Net profit
535.0 K PLN
2024
Assets
76.3 M PLN
2024
Equity
47.3 M PLN
2024
EBITDA
4.7 M PLN
2024
Listing data for Biomaxima on the Warsaw Stock Exchange (GPW) - share price, session change, market segment, industry sector, ISIN code and stock-index membership.
Quotes, shareholders, announcements
BMX
ISIN: PLBIOMX00015
Projects co-financed by the European Union for Biomaxima - total value, EU contribution and the company's largest awards.
Projects
17
EU co-financing
16.3 M PLN
Total project value
34.9 M PLN
Eligible spending
24.2 M PLN
Funds
Operational programmes
Top 8 by EU co-financing
| Project | Fund | EU co-financing | Value | Rate |
|---|
Rate business credibility - Biomaxima.
No ratings
Consumer brand owned by this company.
Umbrella brand
Polski producent podłoży mikrobiologicznych, odczynników i sprzętu do diagnostyki in vitro.
Visit website
Explainer
Boryszew S.A. (KRS 0000063824), headquartered at Aleje Jerozolimskie 92 in Warsaw, is one of the longest-listed Polish industrial holdings on the WSE (since 1996), controlled by entrepreneur Roman Karkosik. The group combines chemical production (Boryszew ERG – automotive fluids), non-ferrous metallurgy (the Skawina mill, Hutmen in Wrocław), automotive plastics (Boryszew Automotive Plastics in Tychy) and global automotive supply (Maflow). Its 2025 financial statements show revenue of around PLN 4.84bn and net profit of PLN 23.6m.
Explainer
Grupa Azoty S.A. (KRS 0000075450), headquartered at ul. Kwiatkowskiego 8 in Tarnów, is Poland's largest chemicals company and a leading European nitrogen-fertiliser producer. It operates four plants – Tarnów (HQ), Police, Kędzierzyn-Koźle and Puławy – and is controlled by the State Treasury. Listed on the WSE since 2008, an mWIG40 constituent, it is delivering the Polimery Police mega-project. Its 2025 financial statements show revenue of around PLN 13.1bn and a net loss of about PLN 4.3bn.
| Period |
|---|
Innowacyjne produkty mikrobiologiczne Contract: RPLU.03.07.00-06-0050/17Programme: Regionalny Program Operacyjny Województwa Lubelskiego na lata 2014-2020Completed | EFRR | 3.0 M PLN | 8.5 M PLN | 60% | 2017–2019 |
Wprowadzenie innowacji poprzez wdrożenie rekomendacji wynikających ze strategii wzorniczej Biomaxima S.A. Contract: POPW.01.04.00-06-0006/17Programme: Program Operacyjny Polska WschodniaCompleted | EFRR | 3.0 M PLN | 6.1 M PLN | 60% | 2017–2018 |
Centrum Badawczo-Rozwojowe BioMaxima Spółka Akcyjna Contract: POIR.02.01.00-00-0236/16Programme: Program Operacyjny Inteligentny RozwójCompleted | EFRR | 2.3 M PLN | 4.7 M PLN | 60% | 2017–2018 |
Wdrożenie do produkcji przez BioMaxima S.A. nowego innowacyjnego szybkiego testu SARS-CoV-2 Ag będącego efektem prac B+R Contract: POPW.01.03.01-06-0012/22Programme: Program Operacyjny Polska WschodniaCompleted | EFRR | 1.8 M PLN | 3.8 M PLN | 60% | 2022–2023 |
Prace badawczo - rozwojowe w zakresie opracowania grupy testów do oznaczania lekowrażliwości Contract: RPLU.01.02.00-06-0020/19Programme: Regionalny Program Operacyjny Województwa Lubelskiego na lata 2014-2020Completed | EFRR | 1.6 M PLN | 2.6 M PLN | 73% | 2020–2023 |
Zwiększenie konkurencyjności Biomaxima poprzez wdrożenie wyników prac B+R nad nowymi bibułowymi krążkami antybiotykowymi Contract: FELU.01.03-IP.01-0040/25Programme: Fundusze Europejskie dla Lubelskiego 2021-2027In progress | EFRR | 1.1 M PLN | 2.3 M PLN | 60% | 2025–2028 |
Zwiększenie konkurencyjności BioMaxima S.A. poprzez uczestnictwo w programie promocji branży sprzętu medycznego Contract: POIR.03.03.03-06-0004/16Programme: Program Operacyjny Inteligentny RozwójCompleted | EFRR | 598.9 K PLN | 1.2 M PLN | 60% | 2016–2019 |
Uruchomienie produkcji testów do oznaczania lekooporności MIC Contract: RPLU.03.07.00-06-0070/19Programme: Regionalny Program Operacyjny Województwa Lubelskiego na lata 2014-2020Completed | EFRR | 589.2 K PLN | 1.2 M PLN | 60% | 2019–2022 |
9 smaller projects not shown.
Company Biomaxima has only one trademark, which is a trademark "BIOMAXIMA".
3 most recent trademarks
BIOMAXIMA
Filing date: 2018-05-21
activeAnswers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
Biomaxima's board has 3 members.
Latest reporting year
2025
Available years
18
Filing entries
0
Average annual headcount for Biomaxima and its capital group by year - figures disclosed in the issuer's annual reports.
Number of employees hired directly by the company.
As of 2024
116
| Year | Headcount | YoY change |
|---|---|---|
| 2024 | 116 | +11 (+10.5%) |
| 2023 | 105 | -8 (-7.1%) |
| 2022 | 113 | +8 (+7.6%) |
| 2021 | 105 | +14 (+15.4%) |
| 2020 | 91 | -7 (-7.1%) |
| 2019 | 98 | -9 (-8.4%) |
| 2018 | 107 | +15 (+16.3%) |
| 2017 | 92 | 0 (0%) |
| 2016 | 92 | +14 (+17.9%) |
| 2015 | 78 | -4 (-4.9%) |
| 2014 | 82 | +37 (+82.2%) |
| 2011 | 45 |
Consolidated headcount across the capital group.
As of 2024
126
| Year | Headcount | YoY change |
|---|---|---|
| 2024 | 126 | +11 (+9.6%) |
| 2023 | 115 | -7 (-5.7%) |
| 2022 | 122 | +11 (+9.9%) |
| 2021 | 111 | +13 (+13.3%) |
| 2020 |
GPW data, retrieved July 3, 2026.
| 98 |
| -6 (-5.8%) |
| 2019 | 104 | -12 (-10.3%) |
| 2018 | 116 | +14 (+13.7%) |
| 2017 | 102 | -2 (-1.9%) |
| 2016 | 104 | +18 (+20.9%) |
| 2013 | 86 |
20 historical registry entries for Biomaxima
Filing documents submitted (2 documents)
Change in Section 1 (basic data)
LU.VI NS-REJ.KRS/21271/23/946/ADE
Filing documents submitted (8 documents)
First fiscal year recorded
LU.VI NS-REJ.KRS/19054/25/872
Filing documents submitted (8 documents)
Public-procurement proceedings in which Biomaxima appears as contractor or contracting authority - total contract value, signing dates, procedures and links to the official notices.
3 most recent proceedings
Dostawa testów diagnostycznych – część II
Dostawa akcesoriów laboratoryjnych
Dzierżawa analizatorów wraz z dostawą odczynników dla potrzeb Medycznego Laboratorium Diagnostycznego SPZOZ w Lublińcu
Competing companies or those operating in the same market segment as Biomaxima (in Lublin, industry: Chemical manufacturing).
ŁOMIANKI· Chemical manufacturing
Revenue 2025: 96.3 M PLN
WARSZAWA· Chemical manufacturing
Revenue 2025: 75.4 M PLN
ŁÓDŹ· Chemical manufacturing
Revenue 2022: 75.1 M PLN
KĘDZIERZYN-KOŹLE· Chemical manufacturing
Revenue 2024: 68.7 M PLN
MYŚLENICE· Chemical manufacturing
Revenue 2024: 57.6 M PLN
GNIEZNO· Chemical manufacturing
Revenue 2022: 46.2 M PLN
